Business Case

Characterized and segmented the treatment ecosystem for relapsing multiple sclerosis (MS) to inform patient- and ecosystem-support strategies and promote a robust launch for a small biotech

Our client, a small biotech firm, was preparing to launch a multiple sclerosis treatment in the post-COVID era and needed to understand how the treatment ecosystem had evolved as a result of COVID. LSC was fortunate to be asked to craft a relapsed MS healthcare ecosystem segmentation tailored to our client’s lead asset. The segmentation hypothesized patient and HCP needs through a detailed patient journey; each process was evaluated in primary market research. The intensive analysis led to the identification of clear “foundational, must-have” and “nice-to-have” programs within relapsed MS, establishing a concrete post-COVID customer engagement model that defined the essential launch initiatives and subsequent priorities.